imipramine has been researched along with dinoprostone in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (27.27) | 29.6817 |
2010's | 8 (72.73) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Duffy, EM; Jorgensen, WL | 1 |
Altenbach, RJ; Brioni, JD; Carr, TL; Chandran, P; Cowart, MD; Esbenshade, TA; Honore, P; Hsieh, GC; Lewis, LG; Liu, H; Manelli, AM; Marsh, KC; Milicic, I; Miller, TR; Strakhova, MI; Vortherms, TA; Wakefield, BD; Wetter, JM; Witte, DG | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Anzini, M; Brogi, S; Butini, S; Campiani, G; Cappelli, A; Caselli, G; Castriconi, F; Gemma, S; Giordani, A; Giorgi, G; Giuliani, G; Lanza, M; Letari, O; Makovec, F; Manini, M; Mennuni, L; Valenti, S | 1 |
Belyakov, S; Dambrova, M; Kazoka, H; Kuznecovs, J; Lebedev, A; Liepinsh, E; Mishnev, A; Orlova, N; Ponomaryov, Y; Vavers, E; Veinberg, G; Vikainis, S; Vilskersts, R; Vorona, M; Zvejniece, L | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E | 1 |
Filipek, B; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pańczyk, K; Pękala, E; Rapacz, A; Słoczyńska, K; Waszkielewicz, AM; Żelaszczyk, D; Żesławska, E | 1 |
Boiti, C; Gobbetti, A; Guelfi, G; Zampini, D; Zerani, M | 1 |
Chang, L; Kim, HW; Lee, HJ; Rao, JS; Rapoport, SI | 1 |
Azab, AN; Nassar, A; Sharon-Granit, Y | 1 |
11 other study(ies) available for imipramine and dinoprostone
Article | Year |
---|---|
Prediction of drug solubility from Monte Carlo simulations.
Topics: Monte Carlo Method; Pharmaceutical Preparations; Solubility | 2000 |
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Humans; Hyperalgesia; Ligands; Mice; Molecular Structure; Pain; Peritonitis; Quinazolines; Rats; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H4; Stereoisomerism; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
Topics: Animals; Area Under Curve; Humans; Intestinal Absorption; Ligands; Male; Metabolic Clearance Rate; Models, Chemical; Models, Molecular; Molecular Structure; Protein Binding; Protein Structure, Tertiary; Pyrrolidinones; Radioligand Assay; Receptor, Serotonin, 5-HT1A; Receptors, Serotonin, 5-HT3; Serotonin 5-HT1 Receptor Agonists; Structure-Activity Relationship | 2013 |
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
Topics: Acetamides; Allosteric Regulation; Animals; Rats; Rats, Wistar; Receptors, sigma; Sigma-1 Receptor; Stereoisomerism; Structure-Activity Relationship | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Topics: Amino Alcohols; Animals; Anticonvulsants; Chemistry, Physical; Dose-Response Relationship, Drug; Drug Design; Epilepsy; Male; Mice; Microsomes, Liver; Molecular Structure; Pilocarpine | 2016 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Topics: Amino Alcohols; Animals; Anticonvulsants; Crystallography, X-Ray; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Mice; Models, Molecular; Molecular Structure; Rats; Seizures; Structure-Activity Relationship | 2017 |
Prostaglandin receptors and role of G protein-activated pathways on corpora lutea of pseudopregnant rabbit in vitro.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adenylyl Cyclases; Analysis of Variance; Animals; Colforsin; Corpus Luteum; Culture Techniques; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; GTP-Binding Protein alpha Subunits, Gi-Go; GTP-Binding Proteins; Imipramine; Luteal Phase; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Progesterone; Protein Kinase C; Pseudopregnancy; Rabbits; Receptors, Prostaglandin; Receptors, Prostaglandin E; Signal Transduction; Statistics, Nonparametric; Staurosporine; Type C Phospholipases | 2001 |
Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder?
Topics: Animals; Arachidonic Acid; Bipolar Disorder; Bupropion; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprostone; Drug Administration Schedule; Frontal Lobe; Humans; Imipramine; Male; Phospholipases A2, Calcium-Independent; Phospholipases A2, Cytosolic; Phosphorylation; Rats; Signal Transduction; Transcription Factor AP-2; Up-Regulation | 2010 |
Psychotropic drugs attenuate lipopolysaccharide-induced hypothermia by altering hypothalamic levels of inflammatory mediators in rats.
Topics: Animals; Carbamazepine; Dinoprostone; Encephalitis; Haloperidol; Hypothalamus; Hypothermia; Imipramine; Inflammation Mediators; Lipopolysaccharides; Lithium; Male; Neoplasm Proteins; Nucleocytoplasmic Transport Proteins; Psychotropic Drugs; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha | 2016 |